Dering J - Search Results

1

Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer.

Cohen B, Shimizu M, Izrailit J, Ng NF, Buchman Y, Pan JG, Dering J, Reedijk M. Cohen B, et al. Among authors: dering j. Breast Cancer Res Treat. 2010 Aug;123(1):113-24. doi: 10.1007/s10549-009-0621-9. Epub 2009 Nov 14. Breast Cancer Res Treat. 2010. PMID: 19915977

2

In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response.

Hurvitz SA, Kalous O, Conklin D, Desai AJ, Dering J, Anderson L, O'Brien NA, Kolarova T, Finn RS, Linnartz R, Chen D, Slamon DJ. Hurvitz SA, et al. Among authors: dering j. Breast Cancer Res Treat. 2015 Feb;149(3):669-80. doi: 10.1007/s10549-015-3282-x. Epub 2015 Feb 8. Breast Cancer Res Treat. 2015. PMID: 25663547

3

Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.

Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, Slamon DJ. Finn RS, et al. Among authors: dering j. Breast Cancer Res Treat. 2007 Nov;105(3):319-26. doi: 10.1007/s10549-006-9463-x. Epub 2007 Feb 1. Breast Cancer Res Treat. 2007. PMID: 17268817

4

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. Finn RS, et al. Among authors: dering j. Breast Cancer Res. 2009;11(5):R77. doi: 10.1186/bcr2419. Breast Cancer Res. 2009. PMID: 19874578 Free PMC article.

5

Recent translational research: microarray expression profiling of breast cancer--beyond classification and prognostic markers?

Wilson CA, Dering J. Wilson CA, et al. Among authors: dering j. Breast Cancer Res. 2004;6(5):192-200. doi: 10.1186/bcr917. Epub 2004 Jul 19. Breast Cancer Res. 2004. PMID: 15318924 Free PMC article.

6

A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. Cheon DJ, et al. Among authors: dering j. Clin Cancer Res. 2014 Feb 1;20(3):711-23. doi: 10.1158/1078-0432.CCR-13-1256. Epub 2013 Nov 11. Clin Cancer Res. 2014. PMID: 24218511 Free PMC article.

7

AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.

Kalous O, Conklin D, Desai AJ, Dering J, Goldstein J, Ginther C, Anderson L, Lu M, Kolarova T, Eckardt MA, Langerød A, Børresen-Dale AL, Slamon DJ, Finn RS. Kalous O, et al. Among authors: dering j. Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5. Breast Cancer Res Treat. 2013. PMID: 24091768

8

HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.

Wilson CA, Cajulis EE, Green JL, Olsen TM, Chung YA, Damore MA, Dering J, Calzone FJ, Slamon DJ. Wilson CA, et al. Among authors: dering j. Breast Cancer Res. 2005;7(6):R1058-79. doi: 10.1186/bcr1343. Epub 2005 Nov 8. Breast Cancer Res. 2005. PMID: 16457687 Free PMC article.

9

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD. Dry JR, et al. Among authors: dering j. Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9. Cancer Res. 2010. PMID: 20215513 Free PMC article.

10

Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

Finn RS, Press MF, Dering J, O'Rourke L, Florance A, Ellis C, Martin AM, Johnston S. Finn RS, et al. Among authors: dering j. Clin Cancer Res. 2014 Feb 1;20(3):736-43. doi: 10.1158/1078-0432.CCR-13-1260. Epub 2013 Nov 6. Clin Cancer Res. 2014. PMID: 24198242

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

31 results

Search Page

Filters